Page 42 - Demo

Gobierno de M%u00e9xico (2023). Cofepris entrega primer permiso de importaci%u00f3n de vector para tratamiento CAR-T para pacientes con c%u00e1ncer de sangre [online] Disponible en: https://www.gob.mx/cofepris/articulos/cofepris-entrega-primer-permiso-deimportacion-de-vector-para-tratamiento-car-t-para-pacientes-concancer-de-sangre [Fecha de revisi%u00f3n 09/12/2923]Gon%u00e7alves GAR, Paiva R de MA (2017) Gene therapy: advances, challenges and perspectives. Einstein 15(3), 369%u2013375.Gonzaludo N, Belmont JW, Gainullin VG, Taft RJ. (2019). Estimating the burden and economic impact of pediatric genetic disease. Genetics in Medicine 21(8):1781%u20131789.Haendel M, Vasilevsky N, Unni D, Bologa C, Harris N, Rehm H, Hamosh A, Baynam G, Groza T, Mcmurry J, Dawkins H, Rath A, Thaxon C, Bocci G, Joachimiak MP, K%u00f6hler S, Robinson PN, Mungall C, Oprea TI. (2020). How many rare diseases are there? HHS Public Access. Nat Rev Drug Discov 19(2):77%u201378.Hampson G, Towse A, Pearson SD, Dreitlein WB, Henshall C (2018) Gene therapy: Evidence, value and affordability in the US health care system. Journal of Comparative Effectiveness Research 7(1):15%u201328.Hemgenix. (2023). HEMGENIX%u00ae (etranacogene dezaparvovec-drlb) [online] Disponible en: https://www.hemgenix.com/why-genetherapy [Fecha de revisi%u00f3n 09/09/2023].J%u00f8rgensen J, Kefalas P (2017) Annuity payments can increase patient access to innovative cell and gene therapies under England%u2019s net budget impact test. Journal of Market Access & Health Policy 5(1):1355203.J%u00f8rgensen J, Servos S, Kefalas P (2018) The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson%u2019s disease. Journal of Market Access & Health Policy 6(1):1500419.Kansteiner F, Becker Z, Liu A, Sagonowsky E, Dunleavy K (2023) Most expensive drugs in the US in 2023. [online] Fierce Pharma. Disponible en: https://www.fiercepharma.com/special-reports/priciest-drugs-2023 [Fecha de consulta 09/09/2023]Kavanagh PL, Fasipe TA, Wun T (2022) Sickle Cell Disease: A Review. JAMA 328(1):57%u201368.Ma CC, Wang ZL, Xu T, He ZY, Wei YQ (2020) The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances 40:107502.Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L%u2019Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., %u2026 Kaspar, B. K. (2017). SingleDose Gene-Replacement Therapy for Spinal Muscular Atrophy. New England Journal of Medicine 377(18):1713%u20131722.Naddaf M (2022) Researchers welcome $3.5-million haemophilia gene therapy - but questions remain. Nature 612(7940):388%u2013389.NICE. (2023a). About | [online] NICE. Disponible en: https://www.nice.org.uk/about [Fecha de consulta 09/09/2023].NICE. (2023b). Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B. [online] NICE. Disponible en: https://www.nice.org.uk/guidance/gid-ta10699/documents/draftguidance [Fecha de consulta 09/09/2023].Papanikolaou E, Bosio A (2021) The Promise and the Hope of Gene Therapy. Frontiers in Genome Editing 3:618346. Rodr%u00edguez-Merchan C, Soroka AB, Feoktistova SG, Mityaeva ON, Volchkov PY (2023) Gene Therapy Approaches for the Treatment of Hemophilia B. International Journal of Molecular Sciences 24(13):10766.Sabatini MT, Chalmers M (2023) The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene Therapies. Pharmaceutical Medicine 37(5):365%u2013375. Shahryari A, Burtscher I, Nazari Z, Lickert H (2021) Engineering Gene Therapy: Advances and Barriers. Advanced Therapeutics 4(9):2100040. Shen G, Gao M, Cao Q, Li W (2022) The Molecular Basis of FIX Deficiency in Hemophilia B. International Journal of Molecular Sciences 23(5):2762.Ulises-Garay O, Caporale JE, Pich%u00f3n-Riviere A, Garc%u00eda-Mart%u00ed S, Mac-Mullen M, Augustovski F (2011) El an%u00e1lisis de impacto presupuestario en salud: puesta al d%u00eda con un modelo de abordaje gen%u00e9rico. Revista Peruana de Medicina Experimental y Salud P%u00fablica 28(3):540%u2013547.Wang D, Tai PWL, Gao G. (2019). Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews. Drug Discovery 18(5):358%u2013378.Wilkins O, Keeler AM, Flotte TR. (2017). CAR T-Cell Therapy: Progress and Prospects. Human Gene Therapy Methods 28(2):61%u201366.Yang G, Cintina I, Pariser A, Oehrlein E, Sullivan J, Kennedy A. (2022). The national economic burden of rare disease in the United States in 2019. Orphanet Journal of Rare Diseases 17(1):1%u201311.Zamora F (2023). TecSalud primero en aplicar terapia g%u00e9nica en paciente privado. [online] Disponible en: https://conecta.tec.mx/es/noticias/nacional/salud/tecsalud-primero-en-aplicar-terapiagenica-en-paciente-privado [Fecha de consulgta 09/12/2023]REFERENCIAS42ISSN: 2448-8461Frontera Biotecnol%u00f3gica | N%u00b0 27 enero-abril 2024